Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Kidney transplant drug shows promise for proteinuria reduction

NCT ID NCT06165601

Disease control Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether dapagliflozin, a diabetes drug, can reduce protein in the urine (proteinuria) in people who have had a kidney transplant and have chronic kidney disease. Researchers followed 55 patients for 6 months to see if the drug lowered protein levels and protected kidney function. The goal was to find a new way to slow kidney damage in transplant recipients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

55 people

The number who actually took part.

Started

Jan 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Initiation of dapagliflozin less than 14 days ago for chronic kidney disease * Glomerular Filtration Rate (GFR) (by CKD-EPI) between 25 and 75 ml.min.1.73m². * Albuminuria/Creatinuria ratio between 200 mg/g and 5000 mg/g * Treatment with an ACE inhibitor or angiotensin 2 receptor blocker (ARA II or sartan) at the maximum tolerated dose for at least 4 weeks. * Age ≥ 18 years Exclusion Criteria: * For study group (CKD Renal transplant recipients) : Renal transplantation \< 1 year old * For the control group (non-transplanted CKD) : history of transplantation of an other organ than a kidney initiation or modification of immunosuppressive therapy less than 6 months ago (except temporary discontinuation for infection or change in dosage) * Type 1 diabetes * Severe liver failure (Child-Pugh stage C) * Intolerance to any of the excipients of Forxiga®, in particular lactose intolerance * Patient undergoing treatment with another SGLT2 inhibitor (sodium-glucose co-transporter type 2) * Patient enrolled in another clinical trial * Pregnancy or breast-feeding * Guardianship or trusteeship * Patient protected by law * Subject not affiliated to a social security scheme, or not benefiting from such a scheme * Patient deprived of liberty * For the retrospective cohort: Patient's refusal to take part in the study after receiving the information note. * For the prospective cohort: Failure to obtain written informed consent after a period of reflection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney diseases

Contacts and locations

Locations

  • University Hospital of Montpellier

    Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.